Literature DB >> 6803564

Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies.

M G Nicholls, H Ikram, E A Espiner, A H Maslowski, M S Scandrett, T Penman.   

Abstract

The hemodynamic and hormonal responses to acute and chronic captopril therapy and to its temporary withdrawal were studied in seven patients with congestive heart failure. Maximal hemodynamic and hormonal effects were reached with 25 to 50 mg doses of captopril. Since plasma angiotensin II levels were significantly higher 6 1/2 hours than 1 hour after administration of captopril, the drug should be given not less often than three times daily. No evidence of hormonal "escape" during long-term (mean 4 1/2 months) captopril therapy was observed, and initial hemodynamic responses were well maintained. Cessation of captopril administration resulted in abrupt increases in circulating angiotensin II levels, in arterial pressure, and in both pulse rate and plasma norepinephrine, but no decrease in cardiac function in the short-term was detected.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803564     DOI: 10.1016/0002-9149(82)90367-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Beneficial effects of captopril in left ventricular failure in patients with myocardial infarction.

Authors:  J P Bounhoure; J G Kayanakis; J M Fauvel; J Puel
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 2.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 3.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

4.  Captopril in heart failure. A double blind controlled trial.

Authors:  J G Cleland; H J Dargie; G P Hodsman; S G Ball; J I Robertson; J J Morton; B W East; I Robertson; G D Murray; G Gillen
Journal:  Br Heart J       Date:  1984-11

5.  Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.

Authors:  A Sigurdsson; O Amtorp; T Gundersen; B Nilsson; J Remes; K Swedberg
Journal:  Br Heart J       Date:  1994-11

6.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Authors:  J G Cleland; H J Dargie; S G Ball; G Gillen; G P Hodsman; J J Morton; B W East; I Robertson; I Ford; J I Robertson
Journal:  Br Heart J       Date:  1985-09

7.  Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure.

Authors:  D Fitzpatrick; M G Nicholls; H Ikram; E A Espiner
Journal:  Br Heart J       Date:  1983-08

Review 8.  Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.

Authors:  Leo F Buckley; Judy W M Cheng; Akshay Desai
Journal:  J Cardiovasc Pharmacol       Date:  2020-06       Impact factor: 3.105

9.  Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis.

Authors:  Mathieu Kerneis; Arnaud Ferrante; Paul Guedeney; Eric Vicaut; Gilles Montalescot
Journal:  Arch Cardiovasc Dis       Date:  2020-10-22       Impact factor: 2.340

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.